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Objective: To assess revision rates after knee arthroplasty by comparing the cumulative results from
worldwide clinical studies and arthroplasty registers. We hypothesised that the revision rate of all
clinical studies of a given implant and register data would not differ signiﬁcantly.
Methods: A systematic review of clinical studies in indexed peer-reviewed journals was performed fol-
lowed by internal and external validation. Parameters for measurement of revision were applied
(Revision for any reason, Revisions per 100 observed component years). Register data served as control
group.
Results: Thirty-six knee arthroplasty systems were identiﬁed to meet the inclusion criteria: 21 total knee
arthroplasty (TKA) systems, 14 unicondylar knee arthroplasty (UKA) systems, one patello-femoral
implant system. For 13 systems (36%), no published study was available that contained revision data. For
17 implants (47%), publications were available dealing with radiographic, surgical or technical details, but
power was too weak to compare revision rates at a signiﬁcant level. Six implant systems (17%) had
a signiﬁcant number of revisions published and were ﬁnally analysed. In general, developers report
better results than independent users. Studies from developers represent an overproportional share of
all observed component years. Register data report overall 10-year revision rates of TKA of 6.2% (range:
4.9e7.8%), rates for UKA are 16.5% (range: 9.7e19.6%).
Conclusion: Revision rates of all clinical studies of a given implant do not differ signiﬁcantly from register
data. However, signiﬁcant differences were found between the revision rates published by developers
and register data. Therefore the different data need to be interpreted in the context of the source of the
information.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The use of artiﬁcial joint implants will exponentially grow in the
next two decades. The implantation rate of knee prostheses will
rise up to 601% until 20301. As life expectancy is growing and the
mean age of patients undergoing primary arthroplasty continues to
decrease, revision rate and longevity of implants are becomingC. Pabinger, EAR (European
stria. Tel: 43-316-908204-0;
drea.berghold@medunigraz.at
hler), gerold.labek@efort.org
s Research Society International. Pincreasingly important. Medical devices are complex assemblies of
multiple components, and the failure of any single component can
lead to unexpected and serious safety problems2. During the last
months quality concerns about arthroplasty have been published3,4
that were not identiﬁed during the pre-marketing tests as stipu-
lated by the regulating authorities. The current study is based on
two projects: (1) EUropean Public Health Outcome Research and
Indicators Collection (EUPHORIC), performed from 2003 to 2008
funded through the ﬁrst EU Health Programme by the Directorate-
General for Health and Consumers of the European Commission,
during which outcome indicators in orthopaedics were deﬁned5.
(2) Quality of Literature in Arthroplasty (QoLA), performed by
EFORT-EAR from 2006 to 2011, during which literature analysis was
performed6.ublished by Elsevier Ltd. All rights reserved.
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would form a “representative sample” providing sufﬁcient data to
assess the quality of prostheses using outcome indicators for
arthroplasty according to the requirements for outcome measure-
ment and quality monitoring of medical devices. Thus the null
hypothesis of the current study stated that the revision rate of
world literature of all clinical studies of a given implant and register
data would not differ signiﬁcantly.Materials and methods
Deﬁnition of parameters
The main outcome indicator evaluated was “Revision for any
reason”. To measure quality, a common set of outcome indicators
was tested among the participating European countries in the
EUPHORIC project, a multidisciplinary project oriented to public
health authorities and policy makers which was funded by the
European Commission (DG Health and Consumers; see http://
www.euphoric-project.eu). One of our authors (GL) was involved
as orthopaedic pilot leader. The outcome indicators “Revision Rate”
and “Revision Burden” deﬁned in EUPHORIC were found to be
fundamental in evaluating outcomes of prostheses from a health
technology assessment point of view. With regard to public health,
these are the two most important indicators for comparative
evaluation in arthroplasty.
Studies with information restricted to individual reasons for
revision (infection, periprosthetic fractures, leg length discrepancy,
etc.), re-revisions and case studies were excluded from our analysis.
The parameter “Revisions per 100 observed component years”
was used to compare revision rates of individual studies with
different follow-up periods and different numbers of implants. This
methodology is a modiﬁcation of a standard procedure in cohort
studies used to describe the risk of cancer in tobacco smoking in
19567,8. It describes a deﬁned risk (revision) of a certain procedure
(arthroplasty) over time, comparable to the parameter “pack years”,
and allows adjustment for time, thusmaking studies comparable9e13.
A value of one revision per 100 observed component years corre-
sponds to a revision rate of 1% at 1 year and a 10% revision rate at
10 years in a linear function10,13. Use of this parameter assumes the
revision rate to decrease over time with a linear function. In view of
the broad scope allowed for the limit values and the large effects
resulting from non-implant-associated impacts on the revision rate,
themathematical uncertainties appearvery lowand shouldnot affect
the overall result6.
A structured literature review concerning every arthroplasty
system with sufﬁcient data available in high-level worldwide
arthroplasty register datasets was conducted as follows6,14.Availability of data, PRISMA statement (Fig. 1)
From 2006 to 2010 a systematic review of the world literature of
arthroplasty was performed in the QoLA project, including more
than 50 orthopaedic surgeons in more than 40 research centres in
20 countries. The data were subjected to internal and external
validation6,13,15.
In the ﬁrst step implants were identiﬁed by name and producer.
The following MeSH descriptor data were used: “Prostheses and
implants” (1966e1970), “joint prostheses” (1971e1997) and “Arthro-
plasty” (E04.555.110), Arthroplasty, Replacement [E04.555.110.110],
Arthroplasty, Replacement [E04.650.110].
In a second step, the orthopaedic literature of indexed peer-
reviewed journals was screened using MEDLINE. Articles were
then reviewed in full text according to a standard protocol.In a third step, eligibility criteria were applied: unambiguous
identiﬁcation of the implant; data of revision unambiguously given
in text, in numbers or in charts.
In a fourth step, prostheses were included if studies contained
“revision for all reasons”. Studies that focused exclusively on other
kinds of revisions alone (mechanical failure, infection, aseptic
loosening, etc.), studies without information about revision rate,
studies about re-revisions, as well as case studies were excluded.
Even though according to the study protocol exclusively clear and
objective data like the numbers of patients were evaluated, unclear
information or wording was observed in some studies. In these
cases a consensus process including the project leader was con-
ducted. Randomly selected datasets were double-checked by an
independent reviewer. None of the cross-checks yielded indica-
tions for mismatch, several outstanding results concerning indi-
vidual implants passed an independent review process and were
published in various orthopaedic journals10,15e17.
In a ﬁfth step, selection was made: only studies dealing with
total knee arthroplasty (TKA) or unicondylar knee arthroplasty
(UKA) were selected. An analysis was performed to assess those
implants with sufﬁcient revision data published to compare
implants with each other. Implants with no revisions published
were excluded. Implants with less than 100 revisions published in
all publications together were found to have too few information to
be included. Only implants with more than 100 revisions published
were included in the current study.
Inclusion period
Literature research was carried out from 2006 until 2010. The
oldest available studies were from 1972.
Origin of publication (developer/independent user/continent)
Each study was evaluated separately. The names of the authors
and the origin of their afﬁliation at the time of publication were
assessed. If the author contributed to the development of a certain
implant, a study in which he was author or co-author was deﬁned
as a developer’s study. Developers were identiﬁed by references in
publications, information material by the manufacturers and
websites. If a study was published by several authors from different
countries, the country of the ﬁrst author’s afﬁliation was used to
classify the country.
Arthroplasty registers
Register data, pooled using the same methodology as described
for clinical studies, served as a control group representing the
average outcome in average patient care to compare results from
publications based on samples. Arthroplasty registers comprise
more data (revisions, implants, observed component years) than all
published studies together. High-level arthroplasty registers
includemore than 95% of all procedures in the given area. Primarily,
data from all arthroplasty registers with internet access were used
as control group, speciﬁcally those from the National Joint Registers
accessible via the summary webpage listing of the EFORT portal18.
Since key factors for a successful arthroplasty register exist since
2007, we focused only on high-value register reports Type
A.1.1.1.16,14,18,19. The data in these registers have gone through
internal and external validation.
Statistical signiﬁcance: Especially when analysing literature from
implant developers and centres of excellence it is advisable to
choose a generous limiting value to signiﬁcance. As described in
QoLA, surgery outcomes depend on individual expertise, circum-
stances in the particular hospital and other potential confounders6.
Fig. 1. PRISMA statement.
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Fig. 2. Observed component years.
Developer contributes to a large proportion of observed component years in USA.
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of limited reproducibility in average patient treatment, the
following criteria were applied:
(1) Deviations from the mean by the ratio of 3 (i.e., 33e300% as the
measure of relevance);
(2) Statistically signiﬁcant deviation due to non-overlapping of
conﬁdence intervals in the main indicator “Revisions per 100
observed component years” as a measure of the quality of
datasets;
(3) Or all studies included show a 100% survival rate, which means
that not a single revision is documented. In this case it is
mathematically impossible to compute conﬁdence intervals,
the deviation factor would be inﬁnitely large.
A difference ratio up to 3 (for instance, the revision rates of
a dataset are three times as high as in the control group) between
the datasets was considered to be explicable by individual exper-
tise, circumstances in the particular hospital and other potential
confounders. The value of 3 was chosen because this value covers
the variability among individual hospitals in countries where
national registers publish these data, such as the Swedish (Hip and
Knee) Registers or the Danish National Arthroplasty Register, as
well as the deviation from the mean of revision rates of individual
implants in various national registers. Calculating the deviation in
outcomes achieved with the same implant in different countries
covered by a National Arthroplasty Register from the worldwide
average of the individual implant (as an estimate of non-implant-
related impact factors) shows that the maximum outliers are also
lower than a ratio of 3.
Note: We would like to explicitly point out that this is a meth-
odological study. All values and factors refer to differences between
datasets, i.e., to the inherent quality of these data. They do not refer
to absolute revision ﬁgures or the outcome of speciﬁc products
assessed.
Results
Availability of data, PRISMA statement (Fig. 1)
Thirty-six different knee implants were identiﬁed having sufﬁ-
cient data in worldwide register datasets. For 13 prostheses not
a single study about “revision for all reasons” could be found in
clinical sample based studies. In the case of 17 prostheses less than
100 revisions were found to be published in the relevant world
literature and, in accordance with the inclusion criteria, were
judged as “implants with too few revisions published” to perform
calculationswith signiﬁcant power. Six implants (four total and two
unicondylar knee replacement systems) with “sufﬁcient revisions
published” remained in 168 clinical studies, concerning 83,495
primary cases and 3448 revision cases. These studies were assessed
in detail (Figs. 1e3, Tables I and II).
Origin of publication (Figs. 2e4, Table I)
Studies from developers represent an overproportional share of
all observed component years. Even though only 18% of all studies
worldwide were published by developers, these studies represent
46% of observed component years and 38% of all cases published. In
the USA 61% of all cases and observed component years were
published by developers. By contrast, in the EU and Asia over 90% of
all cases and all studies and over 80% of all observed component
years are published by independent users. The majority of studies
(91 of 168) were published in the EU, but most cases (47,034 of
83,495) in the USA.Revision rate (Tables I and II)
All prostheses except two report better revision rates in clinical
studies than in registers, but the differences did not reach the
criteria of our deﬁnition of relevance in all cases. The mean revision
rate of TKA in registers is 50% higher than in studies, while the
mean revision rate of UKA in registers is more than double. In ﬁve of
six implants, studies by developers report better results than
studies from independent centres. However, the difference is not
signiﬁcant. The revision rate per 100 observed component years for
primary knee arthroplasty systems ranges from 0.34 to 1.09 in
clinical studies and is comparable to register data, which show
revision rates from 0.49 to 1.9613,17,20.
Sample size: Number of primary implants, length of follow-up
and observed component years did not correlate directly nor
indirectly with revision rate. Regarding LINK uni, the two largest
studies21,22 have an unexplicable low revision rate of 0.14 at 9 years
and 0.09 at 20 years postoperatively versus 0.97 in registers. Similar
ﬁndings were also published for Oxford UKA17.Discussion
Clinical studies display results of individual centres with indi-
vidual prostheses. Even with the large number of cases included in
the current analysise 83,495 from clinical studies and 161,015 from
register datasetsdrevision data from comprehensive clinical
Table I
Origin of publications. Differences between amount of studies, cases and observed
component years and revision rate
Europe USA Asia Other Worldwide
Studies 54% 36% 8% 1% 168 (100%)
Cases (in 1000) 40% 57% 4% 0.1% 84 (100%)
Revisions (in 1000) 48% 49% 3% 0.3% 3.5 (100%)
Observed component
years (in 1000)
31% 66% 3% 0.1% 673 (100%)
Revisions per 100 observed
component years
0.79 0.38 0.5 0.61 0.51
362 
175 
165 
22 
1 
311 
268 
42 
0 
0 100 200 300 400 500 600 700 
worldwide 
USA 
Europe 
Asia 
other  independent origin 
Fig. 3. Primary implants in thousands.
Independent data are found predominantly in Asia and the EU.
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all individual clinical studies, data of different origin are contro-
versial and in part not reproducible in register data. In one implant
up to 11-fold differences are found between the outcome in
arthroplasty registers and the outcome from developers’ studies.
Therefore it has to be questioned, how big sample size of an
individual clinical study would have to be to obtain relevant data:
Using a 95% conﬁdence interval and a statistical power of 80%
13,474 patients would be requested in order to detect a 1% differ-
ence in outcome23. Not a single publication meets this requir-
ementdthis number is only achieved for three implants if all
clinical studies are summarised. In contrast, nowadays registers
obtain more than twice as many primary cases than clinical studies.
Upon rollout of further national registers, data will become even
more.
The parameter “revision per 100 observed component years” is
one possibility of comparing different studies. The linear function
of Revision for any reason is a mathematical simpliﬁcation of
reality, since the risk for septic revision is higher directly post-
operatively and aseptic loosening is known to occur later on. But
also other methods like Kaplan Meier method (with results often
presented in terms of cumulative revision risk), cumulative inci-
dence estimator, the Cox model, hospital-speciﬁc rankings of52 
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Fig. 4. Number of studies.
Most studies worldwide are of independent origin.revision risks and others have statistical errors as Ranstam
describes in a statistical analysis of arthroplasty register data24.
Certainly, there are differences regarding patient selection,
postoperative care, diligence and experience between different
departments. But as evidence from registers shows, within one
country the best performing department shows revision rates of
one-third and the department with the worst outcome shows
revision rates that are 2.5 times higher compared to national
average revision rate13. Therefore deviations from the mean
exceeding a factor of 3 were deﬁned to be signiﬁcant. According to
this deﬁnition developers’ studies tend to report signiﬁcantly better
outcome than independent studies in three cases. Even studies
with more patients and longer follow-up do not lead to better
predictability for users of the products or administrative bodies:
There are large studies17,21,22 with unexplicably low revision rates
compared to registers. If published series by expert centres (e.g.,
developers) set benchmarks and might have an effect on the
submission and acceptance of scientiﬁc papers, can be speculated,
however, it will be impossible to check for confounders due to lack
of access to such information.
Two implant systems were evaluated with very consistent data
whose results of both developers and independent users are
comparable to register data: LCS and PFC total knee prostheses. It is
an interesting observation that the number of component years
published by the developer is more than 10 times lower in these
products (4e6%) as compared to the other prostheses (43e74%)
evaluated in this study.
One limitation of this study might be a possible selection bias,
since clinical studies consist of small numbers of primary implants,
whereas registers consist of larger data. Another limitation is that it
exclusively focuses on revision rate. Revision rate obviously does
not necessarily reﬂect subjective patients satisfaction. Beverland
reported that there are 11 times more “very happy” patients
following hip arthroplasty (54%) than following knee arthroplasty
(4%) although revision data were comparable for both implants25.
Even patients after knee arthrodesis report between 60% and 100%
good and excellent results e depending on previous history of
suffering and deﬁnition of success26e29. Patient satisfaction and
sustainable results should be the goal of knee arthroplasty. Revision
rate is one major indicator to measure the achievement of that goal
since there is a correlation between short-term clinical outcome
and mid-term revision rate30.
Most clinical trials are undertaken in selected centres by a small
number of surgeons, usually on a speciﬁc patient population. In
contrast, register data include many centres, all patients and a large
number of surgeons. This can explain the superior results of clinical
trials compared to register data. The value of arthroplasty register
data and the difﬁculty of interpreting results were addressed by
Graves, who found both to be complementary31.
In conclusionwe found, the different data need to be interpreted
in the context of the source of the information. For that reason,
registers and clinical studies are complementary scientiﬁc tools and
they serve different purposes. It is thus not recommended to use
Table II
Revision rates and follow-up periods. Revisions per 100 observed component years shows differences between worldwide clinical studies, clinical studies published by
developers and worldwide register
AGC
(TKA)
Kinemax
(TKA)
PFC
(TKA)
LCS
(TKA)
Oxford uni
(UKA)
LINK uni
(UKA)
Total All TKA All UKA
Market introduction 1983 1988 1984 1977 1976 1972
Company Biomet Stryker De Puy De Puy Biomet Link
Follow-up (years after market introduction) 28 23 27 34 35 40
Worldwide clinical studies
Primary implants 43,465 2159 15,467 13,911 5217 3276 83,495 75,002 8493
Revisions 1141 140 644 903 449 171 3448 2828 620
OCY observed component years 337,131 17,174 91,637 139,289 41,166 46,824 673,220 585,231 87,989
Number of studies 30 10 55 38 25 10 168 133 35
Clinical studies published by developers
Primary implants 26,261 523 1161 805 1758 1294 31,802 28,750 3052
OCY published by developer (%) 74% 43% 4% 6% 40% 55% 46% 46% 48%
Studies 9 1 7 3 9 1 30 20 10
Worldwide register data
Primary implants 35,284 3844 74,121 31,984 11,985 3797 161,015 145,233 15,782
Revisions 1245 192 1580 854 825 184 4880 3871 1009
OCY observed component years 169,027 27,968 322,403 110,024 42,037 18,985 690,443 629,421 61,022
Revisions per 100 observed component years
All studies 0.34 0.82 0.70 0.65 1.09 0.37 0.51 0.48 0.70
Independent studies 0.79 1.24 0.71 0.65 1.53 0.71 0.78 0.72 1.15
Developers’ studies 0.18 0.25 0.49 0.66 0.43 0.09 0.20 0.20 0.22
Register data 0.74 0.69 0.49 0.78 1.96 0.97 0.71 0.62 1.65
RATIO register/developer 4 3 1 1 5 11 3 3 7
C. Pabinger et al. / Osteoarthritis and Cartilage 21 (2013) 263e268 267clinical studies or register data alone for outcome measurement
and quality monitoring of medical devices.
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